Opiant Pharmaceuticals, Inc. (OPNT)
Opiant Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Santa Monica, CA, US. The stock last traded at $20.65, up 0.00% on the session, giving a market capitalisation of $108.8M. On trailing twelve-month figures it carries a trailing P/E of 30.37, a net margin of 7.4%. Its beta of 0.83 implies it has historically moved less than the broad market.
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
Opiant Pharmaceuticals, Inc. is most often compared with the following Healthcare names: